Back to Results

STERIS plc (STE)

STERIS plc is a healthcare equipment and services company focused on infection prevention. The company operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment includes cleaning chemistries, sterility assurance products, endoscope reprocessing systems, tracking products, endoscopy accessories, washers, sterilizers, and other capital equipment used in sterile processing departments and procedure rooms. This segment also provides installation, maintenance, repair, upgrading, troubleshooting, and related consulting and outsourced sterile processing services. AST supplies contract sterilization and testing services, along with sterilization equipment and control systems, to medical device and pharmaceutical customers. The Life Sciences segment develops and sells consumable products and equipment used in pharmaceutical, cleanroom, and water purity applications. STERIS serves hospitals, healthcare providers, pharmaceutical manufacturers, and related institutions. Founded in 1985, the company is headquartered in Mentor, Ohio, and its common stock trades on the NYSE under the symbol STE.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-STE
$245.38
15.8% Upside
Fair
$252.57
19.2% Upside
Undervalued
Great
—
—
2.52
1.2%
August 10, 2026
26.4x
2.9x
3.5x
20.902 B
22.279 B
9.1%
99.6%
6.7
30.9%
124.3%
Send a message
Valuation • Fair Value

STERIS plc (NYSE-STE) Fair Value by Valuation Model

Compare the primary fair value estimate for STERIS plc (NYSE-STE) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$245.38

Estimated upside of 15.8% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$260.77

Discounted cash flow valuation reference.

Ben Graham Formula Value

$89.07

Classic Ben Graham valuation formula reference.

DDM Fair Value

$271.15

Dividend discount model valuation reference.

EPV Fair Value

$117.88

Earnings power value estimate.

Comps Fair Value

$242.65

Comparable-company valuation reference.

Analyst Price Target

$252.57

Analysts imply upside of 19.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for STERIS plc (NYSE-STE) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for STERIS plc (NYSE-STE)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

5.936 B

Current operating scale indicator.

Revenue Forecast

6.38 B

Forward revenue estimate.

EBITDA

1.598 B

Current operating profitability reference.

EBITDA Forecast

1.776 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review STERIS plc (NYSE-STE) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for STERIS plc (NYSE-STE)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.67

No elevated caution signal from this screen.

Altman Z-Score

6.7

Relatively strong balance-sheet zone.

FCF / Net Income

124.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for STERIS plc (NYSE-STE). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for STERIS plc (NYSE-STE)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 10, 2026

Days to Earnings

20

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

1.2%

Income yield reference.

Upcoming Dividend

2.52

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

30.9%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for STERIS plc (NYSE-STE), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

STERIS plc (NYSE-STE) Stock Forecast & Technical Outlook

Review STERIS plc (NYSE-STE) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for STERIS plc (NYSE-STE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for STERIS plc (NYSE-STE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for STERIS plc (NYSE-STE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for STERIS plc (NYSE-STE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for STERIS plc (NYSE-STE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for STERIS plc (NYSE-STE)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, STERIS plc (NYSE-STE) has a Buy consensus, with 3 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 2
Sell 0
FAQ • Fast Investor Answers

STERIS plc (NYSE-STE) Stock FAQ

Quick answers about STERIS plc (NYSE-STE) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$245.38
Estimated upside 15.8%
Valuation Rating
Undervalued
Estimated upside of 15.8%
Analyst Target
$252.57
Implied upside 19.2%
Financial Health
Great
Current financial-health read

The current fair value estimate for STERIS plc (NYSE-STE) is $245.38. This implies an estimated upside of 15.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 15.8% versus the current market price.

The available analyst price target for STERIS plc (NYSE-STE) is $252.57. The analyst target implies estimated upside of 19.2%.

The current financial health read for STERIS plc (NYSE-STE) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for STERIS plc (NYSE-STE) is August 10, 2026.

Based on the current data, dividend yield is 1.2%, upcoming dividend amount is 2.52.

The current P/E ratio listed for STERIS plc (NYSE-STE) is 26.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for STERIS plc is 20.902 B.

The current enterprise value listed for STERIS plc is 22.279 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for STERIS plc is NYSE-STE, and the stock is listed on NYSE.

STERIS plc (NYSE-STE) is listed on NYSE.

The current debt-to-total-capital ratio listed for STERIS plc is 9.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for STERIS plc is 99.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)
Inspire Medical Systems Inc (INSP) Inspire Medical Systems Inc (INSP)